Answers are grounded in this paper and cite their sources.
Regulatory review reports recommendations for eight new medicines and one biosimilar in the European Union, highlighting expanding therapeutic options across healthcare systems.
In July and August 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the granting of an EU-wide authorisation for 8 new medicines (Table 1) and one new biosimilar medicine (Table 2). The CHMP also recommended the authorisation of 3 new generic medicines and new indications for 8 medicines already authorised in the EU.1
No takes yet. Share an insight, caveat, or question.
Sepodes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: